Abstract
Exogenous insulin administration and oral anti-diabetic drugs are the primary means of treating diabetes. However, tight glycaemic control, with its inherent risk of hypoglycaemia, is required to prevent the microvascular and macrovascular complications of the disease. While islet or pancreas transplantations offer a longer-term cure, their widespread application is not possible, primarily because of a lack of donor tissue, the burden of life-long immunosuppression, and eventual graft rejection. The rapid increase in the incidence of diabetes has promoted the search for alternative cell-based therapies. Here we review recent advances in the directed differentiation of both endocrine and non-endocrine progenitors towards an islet-like phenotype.
Original language | English |
---|---|
Pages (from-to) | 196-204 |
Number of pages | 9 |
Journal | American Journal of Stem Cells |
Volume | 1 |
Issue number | 3 |
Publication status | Published - 2012 |
Externally published | Yes |
Keywords
- Diabetes mellitus
- Endocrine
- Insulin production
- Islet cells
- Progenitor cells